Impact of EML4-ALK Variants on resistance

As of April 20, 2018

Study of 2 groups of patients. Group A = 129 patients, Group B = 577 patients.

The most frequent variants were Variant 1 (43%) and Variant 3 (40%).

“ALK resistance mutations were significantly more common in variant 3 than in variant 1 (57% v 30%).”

“In particular, ALK 1202R was more common in variant 3 than in variant 1 (32% v 0%).”

“Among patients treated with the third-generation ALK TKI lorlatinib, variant 3 was associated with a significantly longer progression-free survival than variant 1.”

https://www.ncbi.nlm.nih.gov/pubmed/29373100

This entry was posted in 3922 - lorlatinib by Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment. Bookmark the permalink.

Leave a Reply